S1P3-ANTAGONISTEN

European patent · EP3086845 · Deleted

Register entry

Publication number
EP3086845
Application number
EP14811790
Kind
European patent with effect for Switzerland and Liechtenstein
Status
Deleted
Specification
Granted
Filed
Nov 28, 2014
Published
Nov 2, 2016
Granted
Nov 20, 2019
Deleted
Nov 30, 2019
Reason
Annual fee unpaid
IPC classes
A61P 25/28 (2006.01)
A61K 31/444 (2006.01)
C07D 403/12 (2006.01)
C07D 213/75 (2006.01)
C07D 401/12 (2006.01)
C07D 413/12 (2006.01)
C07D 417/12 (2006.01)
Priority
EP 13195372 02.12.2013
PCT application
PCT/EP2014/075986 28.11.2014
PCT publication
WO2015/082357 11.06.2015
Filing language
English
Source
Swissreg

History

What the Federal Institute of Intellectual Property published about this title, newest first.

  1. Jun 17, 2020

    Deleted, fee unpaid

    Published in Swissreg on 17.06.2020

  2. Nov 20, 2019

    Granted

    Published in Swissreg on 20.11.2019

Parties

Holder

TEVA Pharmaceutical Industries Limited

Teva Pharmaceutical Industries Limited

5 Basel Street, Petach Tikva 4951033, IL

Inventor

TERSTAPPEN, Georg C.

67271 Battenberg (PFALZ), DE

MICCO, Iolanda

Singapore 138680, SG

GABELLIERI, Emanuele

CH-1018 Lausanne

CARAMELLI, Chiara

I-53018 Sovicille (SI), IT

FEDERICO, Cesare

I-06126 Perugia (PG), IT

MAGNANI, Matteo

I-52015 Pratovecchio (AR), IT

The register names each party by name and address. A holder or agent is linked to an organization where exactly one entity of the commercial register bears its name; the street of a party not so recognised is not shown here.